rjm77me's Blog : GILD - buyer here - normally beat earnings

I bought options in my trading account today
Worries too far away - 8 years away There is a lot of concern about the patent expiration for Atripla, their key drug, in 2018. It's used to treat HIV [human immunodeficiency virus]. But we have confidence in management, and they have three drugs in development that could extend the patent life of that Atripla franchise. They are going to get to Phase III data on one of those drugs in the next couple of months. They just got Phase II data on a drug we call a "quad" pill. The data were good, and it's going to move into Phase III. So looking forward 12 to 18 months, they will have two, maybe three drugs in Phase III development, and they will have seven years to address the patent concern.


Please do your own home work before buying / selling any securities / options.
Some of the note above were published in Barrons write up dated april 5